PP
AQST icon

PDT Partners’s Aquestive Therapeutics AQST Stock Holding History

PDT Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-101,456
Closed -$265K – 947
2022
Q1 		$265K Buy
101,456
+9,845
+11% +$28.8K 0.02% 746
2021
Q4 		$356K Buy
91,611
+15,511
+20% +$77.8K 0.03% 626
2021
Q3 		$332K Sell
76,100
-5,665
-7% -$22.2K 0.02% 573
2021
Q2 		$325K Buy
+81,765
New +$327K 0.02% 603
2021
Q1 		– Sell
-16,486
Closed -$88K – 767
2020
Q4 		$88K Buy
16,486
+87
+0.5% +$521 0.01% 658
2020
Q3 		$80K Buy
+16,399
New +$107K 0.01% 691

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

PDT Partners's AQST Position: Q2 2022 in Review

PDT Partners sold out of Aquestive Therapeutics (AQST) in Q2 2022, closing a stake of 101,456 shares — an estimated $265K sold.

PDT Partners first reported a position in AQST in Q3 2020 and held it in 6 quarters. The position peaked at $356K in Q4 2021. 45 funds tracked by Wall St. Rank hold AQST as of Q2 2022.

  • PDT Partners reported no remaining Aquestive Therapeutics position as of Q2 2022 after selling out during the quarter.
  • PDT Partners sold 101,456 Aquestive Therapeutics shares in Q2 2022, an estimated $265K.
  • PDT Partners first reported a position in Aquestive Therapeutics in Q3 2020 and held it in 6 quarters.
  • PDT Partners's Aquestive Therapeutics position peaked at $356K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.